105 related articles for article (PubMed ID: 15934460)
1. [Significance of MMP2 and MMP9 expression in prostate cancer].
Zhang XY; Hong BF; Chen GF; Lu YL; Zhong M
Zhonghua Nan Ke Xue; 2005 May; 11(5):359-61, 364. PubMed ID: 15934460
[TBL] [Abstract][Full Text] [Related]
2. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer.
Ross JS; Kaur P; Sheehan CE; Fisher HA; Kaufman RA; Kallakury BV
Mod Pathol; 2003 Mar; 16(3):198-205. PubMed ID: 12640098
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas.
Kondratiev S; Gnepp DR; Yakirevich E; Sabo E; Annino DJ; Rebeiz E; Laver NV
Hum Pathol; 2008 Mar; 39(3):337-43. PubMed ID: 18045645
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
Dos Reis ST; Pontes J; Villanova FE; Borra PM; Antunes AA; Dall'oglio MF; Srougi M; Leite KR
J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
[TBL] [Abstract][Full Text] [Related]
8. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
9. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry.
Trudel D; Fradet Y; Meyer F; Harel F; Têtu B
Hum Pathol; 2008 May; 39(5):731-9. PubMed ID: 18329693
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases MMP2 and MMP9 are upregulated by noradrenaline in the mouse neuroendocrine hypothalamus.
Maolood N; Hardin-Pouzet H; Grange-Messent V
Eur J Neurosci; 2008 Mar; 27(5):1143-52. PubMed ID: 18364034
[TBL] [Abstract][Full Text] [Related]
11. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
12. [The significance of matrix metalloproteinases expression in nasal polyps].
Zhang X; Guo Y; Dong Z
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1999 Dec; 34(6):353-5. PubMed ID: 12764844
[TBL] [Abstract][Full Text] [Related]
13. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological significance of aromatase expression in breast cancers].
Lu JS; Li HC; Cao DC; Di GH; Wu J; Shen KW; Shen ZZ; Shao ZM
Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1318-21. PubMed ID: 17217816
[TBL] [Abstract][Full Text] [Related]
15. [Study of the relation between MMP2, MMP9 and nasopharyngeal carcinoma].
Zhang X; Guo Y; Ye Q; Yang Z; Dong Z
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 1999 Aug; 13(8):356-8. PubMed ID: 12541362
[TBL] [Abstract][Full Text] [Related]
16. [Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance].
Liu BQ; Wu YD; Wei JX; Zhang T; Liu RL; Ma TX
Zhonghua Nan Ke Xue; 2007 Nov; 13(11):997-1001. PubMed ID: 18077911
[TBL] [Abstract][Full Text] [Related]
17. [Expression of VEGF in prostate cancer and its correlation with ET-1].
Zhou WQ; Yin HL; Zhang ZY; Yi XM; Ge JP; Zhou SG; Cheng W; Wei W; Ma HQ; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):987-92. PubMed ID: 19102498
[TBL] [Abstract][Full Text] [Related]
18. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer.
Somiari SB; Shriver CD; Heckman C; Olsen C; Hu H; Jordan R; Arciero C; Russell S; Garguilo G; Hooke J; Somiari RI
Cancer Lett; 2006 Feb; 233(1):98-107. PubMed ID: 16473671
[TBL] [Abstract][Full Text] [Related]
19. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication.
Yu W; Liu J; Xiong X; Ai Y; Wang H
Pathol Res Pract; 2009; 205(10):709-15. PubMed ID: 19541433
[TBL] [Abstract][Full Text] [Related]
20. Increased presence of matrix metalloproteinases 2 and 9 in short- and long-term experimental herpes simplex virus encephalitis.
Martínez-Torres FJ; Wagner S; Haas J; Kehm R; Sellner J; Hacke W; Meyding-Lamadé U
Neurosci Lett; 2004 Sep; 368(3):274-8. PubMed ID: 15364410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
